Evidence map›Paper›PMID 24663346›Full record

ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2014

[Importance of FDG-PET/CT for surgery of rectal cancer].

A Wiegering, K Herrmann, C Bluemel, A K Buck, C-T Germer

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Added value of dual-phaseFrontiers in oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

A WiegeringKlinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie, Universitätsklinik Würzburg, Oberdürrbacherstr. 2, 97080, Würzburg, Deutschland, wiegering_a@ukw.de.
K Herrmann
C Bluemel
A K Buck
C-T Germer

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExaminations using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) are becoming increasingly more important in clinical practice for the diagnosis and therapy of cancer patients. QUESTION: What role does FDG-PET/CT examination play in the diagnosis and therapy of rectal cancer?

resultsThe FDG-PET/CT method is especially valuable during postoperative care when a recurrence is suspected. Especially when tumor marker levels rise with no other symptoms, FDG-PET/CT can be used to evaluate unclear lesions in the liver and unclear tissue formations at the surgery site and distinguish between scar tissue and recurring tumors. Currently, there is increasing evidence that a survival prognosis may be possible based on the tracer uptake of FDG-PET/CT. There is also a great interest in the possibility of evaluating the success of neoadjuvant therapy with FDG-PET/CT. DISCUSSION: Despite some limitations FDG-PET/CT plays a significant role in the diagnosis and treatment of patients with rectal cancer.

Indexed as

Fluorodeoxyglucose F18Diagnosis, DifferentialDisease ProgressionFollow-Up StudiesHumansMolecular ImagingMultimodal ImagingNeoplasm Recurrence, LocalNeoplasm StagingPositron-Emission TomographyRectal NeoplasmsRectumSensitivity and SpecificityTomography, X-Ray ComputedFluorodeoxyglucose F18

Identifiers

PMID24663346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.